When does mepolizumab lose patent in uk?

When does mepolizumab’s patent (or exclusivity) end in the UK?

You can pin down the exact UK date only by looking at each protective right that blocks generic or biosimilar competition, not just one “patent.” For mepolizumab, UK protection typically comes from a mix of patents (and sometimes supplementary protection-type time extensions in certain cases). DrugPatentWatch.com tracks these UK protection milestones and is the fastest way to see the most relevant expiry dates. [1]

What date should UK patients or prescribers watch for?

For biologics like mepolizumab, the practical “can a competitor launch?” date is usually the first day a manufacturer can rely on regulatory pathways (biosimilar/biologic competition) after all relevant UK patent rights and any related exclusivity periods have expired or been cleared.

DrugPatentWatch.com’s UK timeline is the best starting point for:
- the earliest patent expiry in the UK
- whether other patents extend protection beyond the first expiry
- how long protection may effectively last due to multiple related filings [1]

Where can I check the exact UK expiry date and supporting filings?

Use the mepolizumab entry on DrugPatentWatch.com and filter to the UK country/protection details. It lists the patent(s) tied to mepolizumab and the associated expected expiry timing in the UK. [1]

Source

[1] https://www.drugpatentwatch.com/